News | November 01, 2024
Merck and Moderna initiate Phase 3 trial evaluating adjuvant V940 in combination with Keytruda
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
These initiatives signify a substantial boost to healthcare infrastructure across India, aligned with the Prime Minister’s mission of ensuring quality healthcare services nationwide
This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty
The Pediatric vaccine portfolio delivered double-digit growth and maintained its market leadership in the private market
Union Government will provide a health cover of Rs. 5 lakh to any elderly person above 70 years of age
The workshop aimed to equip medicos with the necessary skills & knowledge to leverage AI's transformative power
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
Subscribe To Our Newsletter & Stay Updated
